期刊文献+

伊洛前列素对缺氧性肺动脉高压自由基代谢的影响 被引量:3

Effects of iloprost on free radical metabolism of patients with hypoxia induced pulmonary hypertension6
下载PDF
导出
摘要 目的研究雾化吸入伊洛前列素对缺氧性肺动脉高压(HPH)患者自由基代谢的影响。方法在海拔3700 m、4300 m、5200 m和5380 m高原,对56例HPH患者采用雾化吸入伊洛前列素5μg 1次,吸药前、吸入后即刻采血检测超氧化物歧化酶(SOD)、丙二醛(MDA)、乳酸(BLA)、一氧化氮(NO)及其合酶(NOS)的含量。结果吸入后较吸入前,在海拔3700 m,SOD(90.50±7.13)U/ml vs(73.00±10.51)U/ml、NO(73.64±13.42)μmol/L vs(49.60±11.31)μmol/L、NOS(90.50±7.13)U/ml vs(73.00±10.51)U/ml增高,MDA(4.23±0.71)nmol/ml vs(5.61±1.13)nmol/ml、BLA(1.27±0.25)mmol/L vs(1.79±0.62)mmol/L降低,有非常显著差异(P<0.01);在海拔4300 m,SOD(86.78±5.12)U/ml vs(69.39±4.59)U/ml、NO(73.51±6.37)μmol/L vs(48.79±3.76)μmol/L、NOS(44.60±2.64)U/ml vs(40.23±2.31)U/ml增高,MDA(4.24±0.80)nmol/ml vs(6.44±1.51)nmol/ml、BLA(1.46±0.28)mmol/L vs(1.89±0.28)mmol/L降低,有显著差异(P<0.05或P<0.01);在海拔5000 m以上,SOD(86.46±9.05)U/ml vs(66.00±9.95)U/ml、NO(65.50±8.32)μmol/L vs(47.62±11.38)μmol/L、NOS(37.06±2.22)U/ml vs(33.18±2.99)U/ml增高,MDA(6.42±1.59)nmol/ml vs(8.24±2.09)nmol/ml和BLA(2.46±1.24)mmol/L vs(5.18±1.48)mmol/L降低,有非常显著差异(P<0.01)。结论伊洛前列素可改善HPH患者肺氧合效应,增强机体抗氧化酶活性和乳酸清除能力。 Objective To study the effects of aerosol inhalation of iloprost on free radical metabolism of patients with hypoxia induced pulmonary hypertension(HPH).Methods At the high altitude of 3,700 m,4,300 m,5,200 m and 5,380 m above the sea level,56 patients with HPH took the aerosol inhalation of 5 μg iloprost for once.Before and after the inhalation,their blood samples were obtained to detect the contents of superoxide dismutase(SOD),malondialdehyde(MDA),blood lactic acid(BLA),nitric oxide(NO)and nitric oxide synthase(NOS).Results Compared with the situation before the inhalation at the altitude of 3,700 m,the subjects’ SOD [(90.50±7.13)U/ml vs(73.00±10.51)U/ml],NO [(73.64±13.42)μmol/L vs(49.60±11.31)μmol/Land NOS [(90.50±7.13)U/ml vs(73.00±10.51)U/mlincreased and MDA [(4.23±0.71)μmol/L vs(5.61±1.13)μmol/Land BLA [(1.27±0.25)mmol/L vs(1.79±0.62)mmol/Ldecreased after the inhalation,and the differences were very significant(P〈0.01).For people at the altitude of 4,300 m,their SOD [(86.78±5.12)U/ml vs(69.39±4.59)U/ml],NO [(73.51±6.37)μmol/L vs(48.79±3.76)μmol/Land NOS [(44.60±2.64)U/ml vs(40.23±2.31)U/mlincreased and MDA [(4.24±0.80)nmol/ml vs(6.44±1.51)nmol/mland BLA [(1.46±0.28)mmol/L vs(1.89±0.28)mmol/Ldecreased after the inhalation,and the differences were significant(P〈0.05 or P〈0.01).For people at the altitude above 5,000 m,their SOD [(86.46±9.05)U/ml vs(66.00±9.95)U/ml],NO [(65.50±8.32)μmol/L vs(47.62±11.38)μmol/Land NOS [(37.06±2.22)U/ml vs(33.18±2.99)U/mlincreased and MDA [(6.42±1.59)nmol/ml vs(8.24±2.09)nmol/mland BLA [(2.46±1.24)mmol/L vs(5.18±1.48)mmol/Ldecreased after the inhalation.There also were significant differences between the indexes before and after the inhalation(P〈0.01).Conclusion Iloprost can improve the lung oxygenation of patients with HPH and strengthen the abilities of antioxidase and lactate clearance in the body.
机构地区 解放军
出处 《西南国防医药》 CAS 2012年第3期243-245,共3页 Medical Journal of National Defending Forces in Southwest China
基金 国家科技支撑计划项目(2009BAI85B06) 兰州军区基金课题项目(LXH-2009004)
关键词 高原 缺氧性肺动脉高压 伊洛前列素 自由基代谢 血乳酸 high altitude hypoxia induced pulmonary hypertension iloprost free radical metabolism blood lactic acid
  • 相关文献

参考文献5

  • 1中华人民共和国国家职业卫生标准.GBZ92-2008 职业性高原病诊断标准[S].北京:人民卫生出版社,2008.
  • 2Badesch D B,Abman S H,Simonneau G,et al.Medical therapy for pulmonary arterial hypertension:updated ACCP evidence-based clinical practice guidelines[J].Chest,2007,131(6):1917-1928.
  • 3Mikhail G,Gibbes S,Ricardson G,et al.An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension[J].Eur Heart J,1997,18:1499-1504.
  • 4Sablotzki A,Hentschel T,Hofmann S,et al.Inhaled aerosolized iloprost in the evaluation of heart transplant candidates-experiences with 45 cases[J].J Clin Anesth,2006,18(2):108-113.
  • 5Ivy D D,Doran A K,Smith K J,et al.Short-and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension[J].J Am Coll Cardiol,2008,51(2):161-169.

同被引文献37

  • 1崔建华,张西洲,李彬,高亮,马广全,王宏运.高原脱适应的药物防治措施[J].高原医学杂志,2009,19(S1):9-13. 被引量:22
  • 2崔建华,张西洲,王伟,王引虎,哈振德,马勇,邢国祥,张芳.液态氧在高原地区供氧效果的评价[J].中国应用生理学杂志,2004,20(3):283-284. 被引量:5
  • 3崔建华,王引虎,高亮,李彬,张西洲,王宏运,王伟,马勇.驻守海拔5000m以上高原1年返回平原后血液流变学的随访调查[J].中国血液流变学杂志,2006,16(2):246-247. 被引量:11
  • 4崔建华,高亮,张西洲,哈振德,马广全,王宏运,李彬,王伟,马勇.富氧水对高原人体耐缺氧抗疲劳作用机制的探讨[J].临床军医杂志,2007,35(4):495-497. 被引量:9
  • 5张彦博 汪源 刘学良 等.人与高原[M].西宁:青海人民出版社,1996.268.
  • 6Baliga RS, Macallister RJ, Hobbs AJ. New perspectives for the treatment of pulmonary hypertension[J]. Br J Pharmacol,2011,163(1) : 125-140.
  • 7Gall N, Hoeper MM, Humbert M. et al. guidelines for the diagnose is and treatment of pulmonary hypertension the task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology(ESC) and the European respiratory society(ERS), endorsed by the international society of heart and lung transplantation (ISHLT)[J]. Eur Heart J,2009,30:2493 -2537.
  • 8Loyd JE. Pulmonary arterial hypertension: insights from genetic studies[-J] Proc Am Thorac Soc, 2011,8 ( 2 ) : 154- 157.
  • 9Teng RJ, Wu TJ. Persistent puhnonary hypertension of the newborn[J ] Journal of the Formosan Medical Association, 2013,112 (4) : 177 - 184.
  • 10Occhiogrosso M, Omran SS, Altemus M. Persistent pulmonary hypertensim of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies[J]. American Journal of Psychiatry, 2012,169(2) : 134 - 140.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部